Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 2, 2010, Pages 101-105

  Mendes, Gustavo D ^a,b,c   Borges, André ^a   De Cássia Val, Ligia ^a   Patni, Anil K ^d   Reyar, Simrit ^d   Monif, Tausif ^d   Sereno, Daiene ^a   Orellana, Ana Maria M ^a   De Nucci, Gilberto ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSIDADE CAMILO CASTELO BRANCO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d RANBAXY LABORATORIES LTD   (India)

Author keywords

Antibacterial; CAS 64544 07 6; Cefuroxime axetil, bioavailability, administration with food, pharmacokinetics; Tandem mass spectrometry, LC MS MS

Indexed keywords

CEFUROXIME AXETIL; CEROXIM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TANDEM MASS SPECTROMETRY;

EID: 77249087766     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296256     Document Type: Article

References (12)

1. Viberg A, Sandstrm M, Jansson B. Determination of cefuroxime in human serum or plasma by liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):707-10.
2. Powell DA, James NC, Ossi MJ, Nahata MC, Donn KH. Pharmacokinetics of cefuroxime axetil suspension in infants and children. Antimicrob Agents Chemother. 1991 Oct;35(10):2042-5.
3. Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, Al-Bella S, et al. Bioequivalence evaluation of two brands of cefuroxime 500 mg tablets (Cefuzime and Zinnat) in healthy human volunteers. Biopharm Drug Dispos. 2000 Sep;21(6):205-10.
4. Donn KH, James NC, Powell JR. Bioavailability of cefuroxime axetil formulations. J Pharm Sci. 1994 Jun;83(6):842-4.
5. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs. 2001;61(10):1455-500.
6. Finn A, Straughn A, Meyer M, Chubb J. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos. 1987 Nov-Dec;8(6):519-26.
7. Williams PE, Harding SM. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J Antimicrob Chemother. 1984 Feb;13(2):191-6.
8. Chen RR, Lee TY, Hsieh WC. Effect of food on pharmacokinetics of cefuroxime axetil in Chinese subjects. J Formos Med Assoc. 1992 Dec;91(12):1177-81.
9. Ginsburg CM, McCracken GH Jr, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother. 1985 Oct;28(4):504-7.
10. Denooz R, Charlier C. Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by highperformance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 15;864(1-2):161-7.
11. Food and Drug Administration. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. 2003.
12. King R, Bonfiglio R, Fernandez-Metzler C, Miller-Stein C, Olah T. Mechanistic investigation in electrospray ionization. J Am Soc Mass Spectrom. 2000;11:942-50.